. Wh0--informations-diabète,

, Prévalence et incidence du diabète / Données épidémiologiques / Diabète / Maladies chroniques et traumatismes / Dossiers thématiques / Accueil

D. Sur,

, Atlas du Diabète (Fédération International du Diabète)

G. Danaei, C. M. Lawes, and H. S. Vander, « Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration : comparative risk assessment, 2006.

, IWGDF | The International Working Group on the Diabetic Foot

, Qatar National Health report, National Health Service Qatar, 2013.

S. Feldman-billard, Prise en charge du diabète et de ses complications oculaires, Rev Francoph Orthopt. avr, vol.12, issue.2, pp.69-76, 2019.

M. J. Davies, D. 'alessio, D. A. Fradkin, J. Kernan, W. N. Mathieu et al., A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetologia. déc, vol.61, issue.12, pp.2461-98, 2018.

P. Darmon, B. Bauduceau, L. Bordier, J. Bringer, G. Chabrier et al., Prise de position de la Société Francophone du Diabète (SFD) sur la prise en charge médicamenteuse de l'hyperglycémie du patient diabétique de type 2. Médecine Mal Métaboliques, vol.11, p.93, 2017.

, Recommandations de bonne pratique de la Haute Autorité de Santé (HAS), 2013.

M. A. Nauck and J. J. Meier, The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions, Lancet Diabetes Endocrinol. juin, vol.4, issue.6, pp.525-561, 2016.

D. J. Drucker and M. A. Nauck, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, vol.368, p.705, 2006.

, Guidance for Industry, Diabetes Mellit, vol.8, 2008.

S. P. Marso, G. H. Daniels, K. Brown-frandsen, P. Kristensen, J. Mann et al., Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med. 28 juill, vol.375, issue.4, pp.311-333, 2016.

S. P. Marso, S. C. Bain, A. Consoli, F. G. Eliaschewitz, E. Jódar et al., Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.375, pp.1834-1878, 2016.

J. Jendle, G. Grunberger, T. Blevins, F. Giorgino, R. T. Hietpas et al., Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program: Review of Dulaglutide Clinical Trial Program, Diabetes Metab Res Rev, vol.32, issue.8, p.90, 2016.

M. A. Pfeffer, B. Claggett, R. Diaz, K. Dickstein, H. C. Gerstein et al.,

, Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome, N Engl J Med. 3 déc, vol.373, issue.23, pp.2247-57, 2015.

R. R. Holman, M. A. Bethel, R. J. Mentz, V. P. Thompson, Y. Lokhnygina et al., Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med. 28 sept, vol.377, issue.13, p.39, 2017.

A. F. Hernandez, J. B. Green, S. Janmohamed, D. 'agostino, R. B. Granger et al., Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebocontrolled trial. The Lancet, 2018.

D. Sur,

, Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) -Full Text View -ClinicalTrials.gov

S. Gough, B. Bode, V. Woo, H. W. Rodbard, S. Linjawi et al., Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes, Lancet Diabetes Endocrinol, vol.2, issue.11, pp.885-93, 2014.

J. B. Buse, T. Vilsbøll, J. Thurman, T. C. Blevins, I. H. Langbakke et al., Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care, vol.37, pp.2926-2959, 2014.

S. Linjawi, B. W. Bode, L. B. Chaykin, J. Courrèges, Y. Handelsman et al., The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial, Diabetes Ther. févr, vol.8, issue.1, pp.101-115, 2017.

H. W. Rodbard, B. W. Bode, S. B. Harris, L. Rose, L. Lehmann et al., Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial, Diabet Med. 1 févr, vol.34, issue.2, pp.189-96, 2017.

I. Lingvay, F. P. Manghi, P. García-hernández, P. Norwood, L. Lehmann et al., Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial, JAMA. 1 mars, vol.315, issue.9, p.898, 2016.

L. K. Billings, A. Doshi, D. Gouet, A. Oviedo, H. W. Rodbard et al., Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2

, DUAL VII Randomized Clinical Trial, Diabetes Uncontrolled on Metformin and Basal Insulin, 2018.

V. R. Aroda, G. González-galvez, R. Grøn, N. Halladin, M. Haluzík et al., Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial, Lancet Diabetes Endocrinol, 2019.

D. Sur,

P. Tsimikas, A. Billings, L. K. Busch, R. Portillo, C. M. Sahay et al., Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes, Diabetes Obes Metab

D. Sur,

R. Drummond, A. Baru, M. Dutkiewicz, A. Basse, and B. Tengmark, Physicians' real-world experience with IDegLira: results of a European survey, Disponible sur, vol.14, 2018.

D. M. Williams, N. Shrikrishnapalasuriyar, W. Syed, W. L. Yin, R. Chudleigh et al., Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic, Clinical Research & Reviews. 1 nov, vol.12, issue.6, pp.1079-82, 2018.

H. Price, M. Blüher, R. Prager, T. Phan, B. L. Thorsted et al., Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study, Diabetes, Obesity and Metabolism. 1 avr, vol.20, issue.4, pp.954-62, 2018.

D. Sofra, Glycemic Control in a Real-Life Setting in Patients with Type 2 Diabetes Treated with IDegLira at a Single Swiss Center, Diabetes Ther. 1 avr, vol.8, issue.2, p.84, 2017.

G. Wilcox, Insulin and Insulin Resistance, Clin Biochem Rev, 2005.

D. J. Drucker, The Cardiovascular Biology of Glucagon-like Peptide-1, Cell Metabolism. juill, vol.24, issue.1, p.30, 2016.

. Anonymous and . Xultophy,

, European Medicines Agency, 2018.

D. Sur,

, Fiche info -XULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectable -Base de données publique des médicaments

, Haute Autorité de Santé -XULTOPHY (insuline degludec/liraglutide), antidiabétique

D. Sur,

. Vidal--xultophy, 100 U/ml + 3,6 mg/ml sol inj -Synthèse

D. Sur,

J. M. Trujillo, M. Roberts, T. Dex, J. Chao, J. White et al., Low incidence of gastrointestinal adverse events over time with a fixed ratio combination of insulin glargine and lixisenatide versus lixisenatide alone. Diabetes, Obesity and Metabolism, vol.20, pp.2690-2694, 2018.

C. H. Wysham, J. Lin, and L. Kuritzky, Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis

, Postgraduate Medicine, vol.129, issue.4, p.45, 2017.

K. Harris and K. L. Nealy, The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 Diabetes, Annals of Pharmacotherapy. janv, vol.52, issue.1, pp.69-77, 2018.

L. Mandereau-bruno and . En, , 2015.

D. Territoriales, . Socio-Économiques-/-prevalence, and . Pharmacologically-treated, FRANCE IN 2015. TERRITORIAL AND SOCIO-ECONOMIC DISPARITIES, vol.6, 2017.

S. Bellary, A. A. Tahrani, and A. H. Barnett, IDegLira: combining efficacy, durability, and convenience? The Lancet Diabetes & Endocrinology [Internet, 2019.

D. Sur,

, Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes | NEJM

,

, Au moment d'être admis(e) à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés

, Reçu(e) à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité

, Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonoré(e) et méprisé(e) si j'y manque